Denosumab China Phase III Study

Status Completed

Clinical Trial Summary

This study is to evaluate the efficacy and safety of denosumab 60mg for 12 month treatment in Chinese postmenopausal women with osteoporosis at increased risk of fracture.

Clinical Trial Description

The aim of this Phase III, randomized, double-blind, placebo-controlled, parallel-group study is to evaluate the efficacy and safety of denosumab (DMAb) in Chinese postmenopausal women with osteoporosis at increased risk of fracture. The study design consists of two phases: Screening and 12-month Double-Blind treatment phase. Following the Screening phase, all eligible subjects will be randomized to receive Double-Blind DMAb (60 mg) or Placebo study medication in a 3:1 ratio. DMAb 60 mg and placebo will be administered as a single subcutaneous (SC) injection at the beginning of the Double-Blind phase and at 6 months following the initial dose. All subjects will receive daily supplementation of oral elemental calcium (at least 600 mg) and vitamin D (at least 400 IU). The primary objective is to determine the effects of DMAb compared to placebo with respect to mean percent change in BMD at the lumbar spine, as measured by dual-energy x-ray absorptiometry (DXA), from Baseline to Month 12. Secondary objectives include the evaluation between the DMAb and placebo treatment groups: change in BMD: at the lumbar spine (Month 6), total hip (Months 6 and 12), femoral neck (Months 6 and 12) and trochanter (Months 6 and 12); and serum biomarkers of bone formation and resorption (Months 6 and 12). Clinical safety of denosumab will also be assessed in this population. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02014467
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 3
Start date	January 2014
Completion date	August 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT03931109` - Circulating miRNA in Primary Hyperparathyroidism
Not yet recruiting	`NCT03232476` - Effect of Mechanical Loading With PTH on Cortical Bone	Phase 4
Completed	`NCT02884401` - Peri-implant Bone Changes in Post-menopausal Osteoporotic Women	N/A
Completed	`NCT00073190` - Patient- and Physician-Based Osteoporosis Education	Phase 1
Completed	`NCT00402441` - Risedronate in the Prevention of Osteoporosis in Postmenopausal Women	Phase 4
Completed	`NCT03710889` - Early Effects of Abaloparatide on Tissue-Based Indices of Bone Formation and Resorption	Phase 3
Completed	`NCT00010712` - Effects of Black Cohosh on Menopausal Hot Flashes	Phase 2
Recruiting	`NCT05058976` - Romosozumab Use to Build Skeletal Integrity	Phase 4
Active, not recruiting	`NCT05405894` - Efficacy of Zoledronic Acid to Prevent Bone Loss Following Denosumab Discontinuation
Recruiting	`NCT03337971` - Nutritional Supplement and Bone Health in Post-Menopausal Women	N/A
Completed	`NCT03701113` - Milk Protein and Bone Health in Postmenopausal Women	N/A
Completed	`NCT01381588` - The Prevalence of Osteoporotic Vertebral Compression Fractures (OVCF) in Korean Post Menopausal Women	N/A
Completed	`NCT00383422` - Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis	Phase 3
Completed	`NCT00549965` - Satisfaction and Compliance of Risedronate in PMO	Phase 4
Completed	`NCT00035256` - Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis	Phase 4
Completed	`NCT01386281` - Julina Post-marketing Surveillance for Climacteric Symptoms in Japan
Completed	`NCT05266261` - Use of Ibandronate in Diabetic Patients	N/A
Recruiting	`NCT04964388` - Effect of GLP-1 Receptor Agonists on Trabecular Bone Score	Phase 2
Active, not recruiting	`NCT03623633` - Comparative Antiresorptive Efficacy Discontinuation of Denosumab	Phase 4
Recruiting	`NCT05575167` - Single or Repeat Zoledronate Versus Alendronate Following Denosumab (EUROpean Denosumab Effects Consolidation Study)